6Kalayoglu BS, Yeneral MN, Caliskn Y, et al. Time related changes in the incidence, severity, and clinical outcome of hepatic veno-oc clusive disease in hematopoietic stein cell transplantation patients during the past ten years. Transplant Proe, 2005,37:2285. 被引量：1
7Yoshimoto K, Orio N, Okamura T, et al. Recent progress in the diagnosis and therapy for veno occlusive disease of the liver. Leak Lymphomas, 2003,44 : 229. 被引量：1
8Falanga A, Vignoli A, Mavchetti M, et al. Defibrotide reduces procoagulant activity and inereases forolytie properties of endothelial cells. Leukemia,2003,17 : 1636. 被引量：1
9McDonald GB. Review article: management of hepatic disease following naematopoietic cell transplant. Alimentary pharmacology Therapeutics. 2006,24 : 441. 被引量：1
二级参考文献70
1Tanikawa S, Mori S, Ohhashi K, et al. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study. Bone Marrow Transplant, 2000,26 (8): 881-886. 被引量：1
2Petaja J,Pitkanen S,Vettenranta K,et al. Serum tumor marker CA 125 is an early and sensitive indicator of veno-occlusive disease in children undergoing bone marrow transplantation. Clin Cancer Res, 2000,6(2): 531-535. 被引量：1
3Park YD,Yoshioka A,Kawa K,et al. Impaired activity of plasma von Willebrard factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone Marrow Transplant, 2002,29: 789-794. 被引量：1
4Simon M, Hahn T, Ford LA, et al. Retrospective multivariate analysis of hepatic veno occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant ,2001,27(6) :627-633. 被引量：1
5Carreras E,Bertz H,Arcese W,et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Tr 被引量：1
6Moscardo F,Sanz GF,de la Rubia J ,et al. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34+ positive selection. Bone Marrow Transplant, 2001,27 (9): 983- 988. 被引量：1
7Ohashi K,Tanabe J,Watanabe R,et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol, 2000; 64 (1): 32-38. 被引量：1
8Richardson PG,Murakami C,Jin Z,et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure:response without significant toxicity in a high-risk population an 被引量：1
9Zenz T,Rossle M,Bertz H,et al. Severe veno-occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation-role of transjugular intrahepatic portosystemic shunt (TIPS). Liver,2001,21(1):31-36. 被引量：1
10Schlitt HJ, Tischler HJ, Ringe B, et al. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation-clinical and immunological considerations. Bone Marrow Transplant,1995,16(3):473-478. 被引量：1
